MED32 Antibody
Description
Overview of CD32 (FcγRII) Antibodies
CD32, also known as Fc gamma receptor II (FcγRII), is a 40 kDa transmembrane glycoprotein belonging to the immunoglobulin superfamily. It functions as a low-affinity receptor for aggregated IgG and immune complexes, mediating immune responses such as phagocytosis, platelet activation, and immunomodulation .
Antibody Binding and Effector Mechanisms
CD32 antibodies target epitopes on FcγRII isoforms to modulate immune responses:
CD32 Isoform-Specific Roles
Oncology
-
Margetuximab-cmkb: Engineered anti-HER2 antibody with enhanced FcγRIIIA binding for improved ADCC in HER2+ breast cancer .
-
Anti-CD32B (2B6): Humanized monoclonal antibody tested in systemic light-chain amyloidosis to deplete clonal plasma cells .
Infectious Diseases
-
SARS-CoV-2 Neutralization: FcγRIIA engagement enhances neutrophil-mediated viral clearance via ADCC .
-
HIV and Influenza: Antibodies leveraging FcγRII pathways show promise in preclinical models for viral neutralization .
Preclinical Studies
-
CD32B in Amyloidosis: >99% of clonal plasma cells in systemic amyloidosis express CD32B, making it a viable target for monoclonal antibody therapy .
-
Fc Engineering: Modifications (e.g., L234F, D265A) reduce FcγRIIB binding to minimize immunosuppressive signals in checkpoint inhibitors .
Clinical Trials
Challenges and Future Directions
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- MED32 plays a crucial role in root development and senescence, two processes that are regulated by redox mechanisms. PMID: 26195288
Q&A
Here’s a structured collection of FAQs for MED32 Antibody tailored to academic research, incorporating methodological guidance and evidence-based insights:
Advanced Research Questions
What strategies resolve contradictions between MED32 antibody signals in WB vs. IHC?
Common causes and solutions:
How to design experiments investigating MED32’s role in immune modulation?
-
In vitro: Use THP-1 macrophages or primary dendritic cells; stimulate with LPS/IFN-γ and measure cytokine profiles (IL-6, TNF-α) via multiplex assays .
-
In vivo: Employ MED32-deficient mouse models with DSS-induced colitis; assess histopathology and immune cell infiltration .
-
Mechanistic studies: Combine ChIP-seq (MED32 binding sites) with RNA-seq to identify downstream targets .
Can MED32 antibodies cross-react with paralogs (e.g., MED12/26) in co-IP experiments?
-
Perform BLAST alignment of immunogen sequences to identify homology regions .
-
Validate using overexpression systems: Transfect HEK293T cells with FLAG-tagged MED12/26 and test for co-precipitation .
-
Employ cross-adsorption with recombinant paralog proteins during antibody purification .
Methodological Best Practices
How to optimize MED32 antibody dilution for low-abundance targets?
-
Conduct checkerboard titrations (e.g., 1:50–1:2000 dilutions) using positive/negative control tissues.
-
For flow cytometry, use Fc-blocking reagents (e.g., CD16/32 antibodies) to minimize background .
-
Quantify signal-to-noise ratios using imaging software (e.g., ImageJ) .
What controls are critical for CRISPR-mediated MED32 knockout studies?
Data Interpretation Guidance
How to distinguish MED32-specific effects from off-target immune responses in in vivo models?
-
Depletion assays: Administer MED32 antibodies to WT vs. Med32<sup>-/-</sup> mice; phenotype differences indicate specificity .
-
Cytokine profiling: Compare serum levels of IL-10, TGF-β, and IL-17A using Luminex assays .
-
Single-cell RNA-seq: Analyze myeloid cell subsets in target tissues to identify MED32-dependent pathways .
